



## **EXACT Therapeutics announces grant of immunotherapy patent**

Oslo, Norway, September 25, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology, has been informed that the Intellectual Property Office in United Kingdom will today grant EXACT its United Kingdom Patent No: 2 605 996 entitled "Enhancement of Treatment with Immunotherapeutic Agents".

The granted patent covers EXACT's proprietary Acoustic Cluster Therapy (ACT®) in combination with immunotherapy in cancer and autoimmune disease patients.

Per Walday, CEO of EXACT comments, "We are very pleased with the granting of this important patent in its first territory. Expanding our patent protection is a core strategy, reflecting the remarkable innovation coming out from our labs. In addition, it supports our strategic oncology focus."

For further information, please contact:

Per Walday

CEO EXACT Therapeutics

Email: [per.walday@exact-tx.com](mailto:per.walday@exact-tx.com)

About EXACT Therapeutics:

EXACT is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to enable or significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. [www.exact-tx.com](http://www.exact-tx.com)

About ACT®:

- ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
- ACT is being tested in the clinic and has released positive interim data. It is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
- Initial focus of the company is oncology. The ACT platform has potential across many therapeutic areas (including CNS, immunotherapy) and product classes.



Forward looking statements:

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.